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We examined the molecular mechanism of OCT4 gene regulation by polyomavirus enhancer activa-
tor 3 (PEA3) in NCCIT cells. Endogenous PEA3 and OCT4 were signiﬁcantly elevated in undifferenti-
ated cells and reduced upon differentiation. PEA3 knockdown led to a reduction in OCT4 levels.
OCT4 promoter activity was signiﬁcantly up-regulated by dose-dependent PEA3 overexpression.
Deletion and site-directed mutagenesis of the OCT4 promoter revealed a putative binding site within
the conserved region 2 (CR2). PEA3 interacted with the binding element within CR2 in NCCIT cells.
This study reveals the molecular details of the mechanism by which the oncogenic factor PEA3 reg-
ulates OCT4 gene expression as a transcriptional activator.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction the N-terminal activation domain is more potent [9,10]. PEA3 isThe ETS transcription factors were ﬁrst identiﬁed in the avian
E26 erythroblastosis virus, from which the name of the family is
derived (E26 transformation–speciﬁc) [1,2]. The human genome
encodes 27 members of the ETS family. ETS transcription factors
are characterized by a highly conserved 85 amino acid DNA-
binding domain [3]. The core recognition sequence of the ETS
domain-binding site (EBS) is a purine-rich motif [50-GGA(A/T)-30]
present in the promoter or enhancer regions of ETS target genes
[1,4]. ETS factors act as positive or negative regulators of the
expression of downstream target genes in biological processes
such as differentiation, proliferation, and oncogenesis [5–7]. Poly-
omavirus enhancer activator 3 (PEA3, also called ETV4 or E1AF),
which belongs to the PEA3 subfamily of ETS proteins [8], contains
acidic transactivation domains at the N- and C-termini; of these,expressed in numerous organs during embryonic and adult devel-
opment [11–13]. In normal development, PEA3 plays a role in tran-
scriptional control in motor neuron and mammary gland
development [14,15]. However, deregulation of PEA3 is associated
with a variety of cancers, including colon, breast, ovarian, prostate,
and esophageal tumors [16–18], supporting the notion that PEA3
plays a crucial role as an oncogenic activator.
OCT4, ﬁrst identiﬁed as a transcription factor speciﬁc to early
embryonic development, is a master regulator of the induction
and maintenance of cellular pluripotency [19,20]. In embryonic
stem (ES) cells, deregulation of OCT4 expression leads to a loss of
pluripotency and induces differentiation, suggesting that OCT4 lev-
els must be kept within a narrow range to maintain pluripotency,
and further implying that OCT4 levels are tightly regulated [21].
Recently, however, OCT4 expression has been detected in a variety
of human cancer cells [22–25]. For instance, OCT4 is expressed by
glioma cells, in which it promotes colony formation [26]. In blad-
der cancer cells, overexpression of OCT4 enhances migration and
invasion [27]. Likewise, OCT4 increases transmigration capacity
in melanoma cells, leading to higher invasiveness and aggressive-
ness [28]. These observations suggest that deregulation and dys-
function of OCT4 may contribute to malignant transformation
and the establishment of a ‘‘cancer stem cell’’ phenotype. OCT4 is
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tumors, which exhibit gene expression patterns similar to those of
ES cells [29–31]. Repression of OCT4 expression in cancer stem
cell-like cell leads to apoptosis and the inhibition of cancer growth,
indicating that OCT4 may be important in cancer therapy [32].
Although both PEA3 and OCT4 have been implicated in a variety
of tumorigenic events, no study to date has described their molec-
ular relationship at the transcriptional level. To address this issue,
we investigated whether PEA3 can act as an upstream effector to
regulate the OCT4 gene in NCCIT human embryonic carcinoma
(EC) cells. These cells exhibit an intermediate phenotype between
seminoma and embryonal carcinoma cells, and are a useful tool for
studying the relationship between seminoma and non-seminoma
tumorigenesis, as well as stem cell pluripotency [33].
2. Materials and methods
2.1. Cell culture and differentiation
Human EC NCCIT cells (American Type Cell Collection) were
grown as previously described [34]. To induce differentiation,
NCCIT cells were treated with 10 lM retinoic acid (RA; Sigma–
Aldrich, St. Louis, MO, USA) and harvested at various time points
(0, 2, 4, 6, 8, and 10 days) for quantitative RT-PCR andWestern-blot
analyses.
2.2. Preparation of short hairpin RNA against PEA3
Two target sequences for PEA3 RNA interference were gener-
ated using the Gene Link shRNA Design Guidelines website
(http://www.genelink.com/sirna/shrnai.asp) for maximum silenc-
ing efﬁciency. As previously described [35], two double-stranded
oligonucleotides were generated by annealing 50-GATCCGTCACT
TCCAGGAGACGTGGAAGCTTGCACGTCTCCTGGAAGTGACTTTTTTGG
AAGC-30 and 50-GGCCGCTTCCAAAAAAGTCACTTCCAG]GAGACGTG




yield PEA3 shRNA 2 (PEA3 sense and antisense sequences are
underlined; hairpin loop structure containing the HindIII restric-
tion site is italicized). The resultant double-stranded oligos were
inserted into the pGSH1-GFP shRNA vector (Genlantis, San Diego,
CA, USA) digested with BamHI and NotI. The pGSH1-GFP-luciferase
shRNA vector (Genlantis) was used as a control.
2.3. Plasmid construction
We used various luciferase reporter constructs, including
human OCT4 promoter derivatives [-2601-Luc, -2329-Luc, -1588-
Luc, and -1427-Luc] and a pGL3-ti minimal promoter (adenovirus
major late promoter TATA box and mouse terminal deoxynucleoti-
dyl transferase gene initiator sequence) reporter construct contain-
ing the OCT4 promoter conserved region 2 (CR2-ti-Luc), described
previously [34,36,37]. Site-directed mutagenesis was performed,
using the QuickChange kit (Stratagene, La Jolla, CA, USA), to destroy
a putative PEA3-binding element [also called the EBS] within the
OCT4 promoter (-2601-Luc) and the exogenous minimal promoter
CR2-ti-Luc. To this end the putative EBS in CR2 was replaced with
the XbaI restriction site (TCTAGA) using the primers 50-GGGTTGGG
GAGCtctagaCAGTCCCCAGGG-30 (forward) and 50-GGTTGGGGAGCt
ctagaCAGTCCCCAGGG-30 (reverse), and this sequence was inserted
upstream of the gene encoding luciferase to generate EBS-mutant
promoters [-2601⁄-Luc and CR2⁄-ti-Luc]. The full-length PEA3
cDNA (Open Biosystems) was ampliﬁed using the primers 50-TAA
TGGATCCATGGAGCGGAGGATGAAAG-30 (forward) and 50-TAATCTCGAGCTAGTAAGAGTAGCCACCCTT-30 (reverse), and then inserted
into FLAG-tagged pcDNA3.1+ expression vector. A dominant-nega-
tive (DN) form of PEA3 (PEA3 DN) was generated by deleting amino
acids 1–281 by PCR ampliﬁcation of the PEA3 wild-type (WT)
expression vector, using the primers 50-ATTAGATATCACAGAGGGC
TTCTCTGGG-30 (forward) and 50-TAATCTCGAGCTAGTAAGAGTAG
CCACCCTT-30 (reverse), followed by insertion of the ampliﬁed
sequence into FLAG-tagged-NLS pcDNA3.1+ vector. All cloned
PCR products and reporter plasmids were veriﬁed by sequencing.
2.4. Transient transfection, RNA preparation, and quantitative reverse
transcription-polymerase chain reaction (qRT-PCR)
NCCIT cells (3  105) were transfected with pGSH1-GFP-PEA3
shRNA1/2 using the 25-kDa linear-polyethylenimine (L-PEI) trans-
fection reagent (Polysciences, Warrington, PA, USA), as described
previously with minor modiﬁcations [38]. To induce PEA3 overex-
pression, a FLAG-tagged PEA3 WT expression vector was delivered
into NCCIT cells. pGSH1-GFP-luciferase shRNA and FLAG-tagged
pcDNA3.1+ vectors were used as controls. Total RNA was isolated
from NCCIT cells (naive or differentiated; transfected with PEA3
WT or PEA3 shRNA1/2), as previously described [35]. For qRT-
PCR, cDNA obtained from NCCIT cells was ampliﬁed with real-time
PCR mix containing the DNA-binding dye SYBR Green (Bioneer,
Daejeon, South Korea). The forward and reverse primers were as
follows: PEA3 (192 bp), 50-CTCGCTCCGATACTATTATG-30 (forward)
and 50-CTCATCCAAGTGGGACAAAG-30 (reverse) [39]; OCT4
(97 bp), 50-CCCCTGGTGCCGTGAA-30 (forward) and 5-GCAAATTGCT
CGAGTTCTTTCTG-30 (reverse); and GAPDH (226 bp), 50-GAAGGTGA
AGGTCGGAGTC-30 (forward) and 50-GAAGATGGTGATGGGATTTC-30
(reverse). GAPDH cDNA was ampliﬁed from all samples as a nor-
malization control. PCR conditions were as follows: 94 C for
10 min; 40 cycles of 94 C for 15 s and 60 C for 30 s; and 72 C
for 30 s. Relative quantiﬁcation of the expression levels was deter-
mined using the 2DDCt method [40].
2.5. Western blot analysis
NCCIT cells were transfected with FLAG-tagged PEA3 WT or
PEA3 shRNA1/2 using the 25-kDa L-PEI transfection reagent (Poly-
sciences), and harvested 48 h after transfection. Western blotting
was performed using primary antibodies (anti-OCT3/4monoclonal:
1:2500, Santa Cruz Biotechnology, Dallas, TX, USA; anti-PEA3 poly-
clonal: 1:2500, US biological, Swampscott, MA, USA; anti-FLAG
monoclonal: 1:2500, Sigma–Aldrich; anti-b-actin monoclonal:
1:2500, Santa Cruz Biotechnology) and horseradish peroxidase–
conjugated secondary antibodies (1:5000, Santa Cruz
Biotechnology).
2.6. Transient transfection and reporter assays
pGL3-basic reporter vectors (Promega, Madison, WI, USA) con-
taining the WT OCT4 promoter, or deletion or site-directed
mutants, were co-transfected along with FLAG-tagged WT or dele-
tion mutant PEA3 into NCCIT cells, using the ExGen500 in vitro
transfection reagent (Fermentas, Hanover, MD, USA), as described
previously [41].
2.7. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously, with minor
modiﬁcations [35]. Chromatin from naive NCCIT cells was pre-
cleared for 4 h at 4 C with salmon sperm DNA and Protein G
PLUS-agarose beads (Santa Cruz Biotechnology). Approximately
1 ml of pre-cleared protein lysate was incubated overnight with
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logical, Swampscott, MA, USA) or normal rabbit IgG (Cell Signaling
Technology, Boston, MA, USA). Immunoprecipitated DNA was then
used as the template for real-time PCR with primers speciﬁc to the
OCT4 promoter. Primer sequences were as follows: [2613 to
2396, depicted as ‘a’: (forward) 50-GGGGAACCTGGAGGATGGCA
AGCTGAGAAA-30 and (reverse) 50-GGCCTGGTGGGGGTGGGAGGA
ACAT-30], [CR2 (1513 to 1316), depicted as ‘b’: (forward) 50-T
GAGGGGATTGGGACTGGGG-30 and (reverse) 50-TATCTGACTTCAGG
TTCAAA-30], [237 to 136, depicted as ‘c’: (forward) 50-GAGGGG
CGCCAGTTGTGTCTCCCGGTTTT-30 and (reverse) 50-GGGAGGTGGG
GGGAGAAACTGAGGCGAAGG-30].2.8. Statistical analysis
All experiments were performed independently at least three
times. Data shown in ﬁgures are means ± standard deviations
(S.D.) over all trials. The data were analyzed by t-test or ANOVA
with Duncan’s multiple range procedure for multiple comparisons,
using the SigmaPlot 10 program (Systat Software, San Jose, CA,
USA). In all experiments, P < 0.05 was considered statistically
signiﬁcant.Fig. 1. Expression levels of endogenous OCT4 and PEA3 in naive and differentiated
NCCIT cells. To induce differentiation, NCCIT cells were treated with 10 lM RA for
10 days. (A) Real-time PCR was performed to determine the OCT4 and PEA3 mRNA
levels in naive and differentiated NCCIT cells. Transcript levels were normalized to
the level of GAPDH mRNA. ⁄⁄P < 0.01. (B) Western blot analysis of PEA3 and OCT4 in
NCCIT cells at the indicated time points (0, 2, 4, 6, and 8 days) during RA-mediated
differentiation. The control sample was treated with vehicle (ethanol) for 10 days.3. Results and discussion
3.1. Expression analysis of PEA3 and OCT4 in NCCIT cells
To examine the expression patterns of PEA3 and OCT4 in naive
and differentiated NCCIT cells, we exposed the cells to RA for
10 days to induce differentiation. The mRNA levels of PEA3 and
OCT4 were signiﬁcantly reduced (7.5-fold and 19.7-fold, respec-
tively) in differentiated NCCIT cells relative to naive cells
(Fig. 1A). Moreover, PEA3 and OCT4 protein levels signiﬁcantly
decreased upon time-dependent RA treatment (0, 2, 4, 6, and
8 days) (Fig. 1B), suggesting that the expression levels of OCT4
and PEA3 are coordinated in a manner that depends on differentia-
tion status. RA plays important roles in the regulation of biological
events such as differentiation, embryogenesis, and homeostasis
[42]. In addition, treatment of EC cells with RA represses the expres-
sion of several oncogenic factors and suppresses tumorigenesis,
suggesting a link between enforced pluripotency and transforma-
tion [43]. PEA3 expression is down-regulated during RA-induced
differentiation of mouse embryonic cells, suggesting that PEA3
exerts a regulatory function during mouse embryogenesis [8].
OCT4 expression is also repressed during RA-mediated differentia-
tion in both EC and ES cells [37,44,45]. In addition, both Oct4 and
Pea3 transcripts are rapidly reduced following RA treatment of
P19 mouse EC cells [46], suggesting their co-relationship at the
transcript level during RA-mediated differentiation.
To determine the more direct expressional relationship
between PEA3 and OCT4, we next investigated the effect of overex-
pression and knockdown of PEA3 on OCT4 expression. To induce
PEA3 overexpression, a FLAG-tagged PEA3 WT expression vector
was delivered into NCCIT cells. As determined by qRT-PCR, overex-
pression of PEA3 (with 8-fold increase, respectively) induced OCT4
expression (with 4-fold increase, respectively; Fig. 2A, left panel).
The relative increase of both PEA3 and OCT4 protein expression
was conﬁrmed by Western blot analysis using speciﬁc antibodies
against PEA3 and OCT4. Exogenous PEA3 expression was also con-
ﬁrmed by anti-FLAG antibody (Fig. 2A, right panel). Quantitative
RT-PCR revealed that shRNA-mediated knockdown of PEA3 (with
decrease of 60%, respectively) signiﬁcantly decreased the level of
endogenous OCT4 mRNA (with decrease of 60%, respectively,
Fig. 2B, left panel). Decrease of their protein expression was also
conﬁrmed by Western blot analysis using speciﬁc antibodiesagainst PEA3 and OCT4 (Fig. 2B, right panel). Taken together, these
data indicate that PEA3 activates OCT4 gene expression, implying
that PEA3 may act a positive effector of OCT4 expression in human
EC cells.
OCT4 promoter activity is activated in a dose-dependent man-
ner by PEA3 overexpression, and activation requires the PEA3
transactivation domain.
The human OCT4 50-upstream region contains four highly con-
served regions (CR1–4) that contain important cis-regulatory
elements [34,47]. To further investigate the functional relationship
between PEA3 and OCT4 at the transcriptional level, we co-trans-
fected an OCT4 upstream promoter–reporter construct (-2601-
Luc) with increasing amounts of PEA3 expression vector (Fig. 3A).
OCT4 promoter activity increased signiﬁcantly as a function of
PEA3 expression level (Fig. 3B). Furthermore, OCT4 promoter acti-
vation was PEA3-speciﬁc, as revealed by the effect of co-transfec-
tion of DN PEA3 lacking the N-terminal transactivation domain
(TAD; amino acids 49–80) [9]. OCT4 promoter activity was signiﬁ-
cantly down-regulated in a dose-dependent manner by overex-
pression of PEA3 DN, even in the presence of PEA3 (Fig. 3C).
These data suggest that PEA3 can act as a transcriptional activator
of OCT4 gene expression, and that this function requires the N-ter-
minal TAD of PEA3.
3.2. The effect of PEA3 on the transcriptional activity of a series of
OCT4 promoter deletion mutants
We previously reported that deletion of the OCT4 promoter
upstream region from 1588 to 1427, which contains part of
the CR2 sequence, resulted in signiﬁcant down-regulation of
promoter activity, suggesting the presence of important regulatory
element(s) in this region [34]. To further deﬁne the region of the
OCT4 promoter that governs PEA3-mediated transcriptional
Fig. 2. Effect of PEA3 overexpression and shRNA-mediated knockdown on OCT4 expression in NCCIT cells. (A) NCCIT cells were transfected with FLAG-tagged PEA3 WT and
harvested 48 hours after transfection. FLAG-tagged pcDNA3.1+ was used as a control. (Left panel) Levels of PEA3 and OCT4 mRNA were measured by real-time PCR,
normalized against the level of GAPDH in the same samples, and further normalized to the levels in control transfectants. ⁄⁄P < 0.01. (Right panel) Protein levels of PEA3 and
OCT4 were analyzed by Western blotting using anti-PEA3, anti-FLAG, and anti-OCT3/4 antibodies. b-actin was used as an internal control for normalization of total protein
content. (B) NCCIT cells were transfected with pGSH1-GFP-PEA3 shRNA1/2, and harvested 48 h after transfection. pGSH1-GFP-luciferase shRNA vector was used as a control.
(Left panel) Levels of PEA3 and OCT4 mRNA were measured as described above. ⁄⁄P < 0.01. (Right panel) Protein levels of PEA3 and OCT4 were analyzed, as described above
using anti-PEA3 and anti-OCT3/4 antibodies.
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trolled by deletion mutants (-2601-Luc, -2329-Luc, -1588-Luc,
and -1427-Luc) of the OCT4 promoter, and co-transfected these
constructs into NCCIT cells along with PEA3 expression vector
(Fig. 4A). PEA3 effectively induced the transcriptional activity of
OCT4 promoter–reporter vectors (-2601-Luc, -2329-Luc, -1588-
Luc), but PEA3 could not activate a deletion mutant (-1427-Luc)
(Fig. 4B). This observation suggests that this region between
1588 and 1427 contains an EBS, with the consensus sequence
(GGAA/T) recognized by a variety of ETS family members, and that
PEA3 may interact with this putative regulatory region.
3.3. The OCT4 promoter conserved region 2 (CR2) is important for
transcriptional activation by PEA3
We analyzed these sequences using the TFSEARCH database
(http://mbs.cbrc.jp/research/db/TFSEARCH.html) and found a
putative ETS binding element (1482AGGAAG1477) within CR2
(1512 to 1316). To further investigate the importance of the
putative EBS, which contains the GGAA consensus sequence within
CR2, we employed different promoter–reporter constructs derived
from the native OCT4 promoter (-2601-Luc) and the exogenous
minimal ti promoter (CR2-ti-Luc), as described previously [37].
Mutant reporter constructs (-2601⁄-Luc and CR2⁄-ti-Luc) were
generated by replacing the putative EBS within CR2 with the XbaI
restriction site (TCTAGA). We co-transfected each of these con-
structs into NCCIT cells along with PEA3 expression vector, andmeasured the resultant transcriptional activity (Fig. 5A). In the
presence of PEA3, WT promoter–reporter constructs (-2601-Luc
and CR2-ti-Luc) were signiﬁcantly activated, whereas the mutant
constructs (-2601⁄-Luc and CR2⁄-ti-Luc) were not, suggesting that
PEA3 positively regulates OCT4 promoter activity via the putative
EBS within CR2 (Fig. 5B). To determine whether CR2 activation
was PEA3-speciﬁc, we co-transfected the CR2-ti-Luc construct into
NCCIT cells along with increasing amounts of PEA3 expression vec-
tor (Fig. 6A). Transcriptional activity of the CR2-ti-Luc construct
was signiﬁcantly up-regulated by PEA3 overexpression in a dose-
dependent manner (Fig. 6B), whereas PEA3-mediated activation
of the CR2-ti-Luc construct was signiﬁcantly down-regulated in a
dose-dependent manner by co-expression of PEA3 DN (Fig. 6C),
conﬁrming the importance of the EBS in CR2 for the transcriptional
activation by PEA3.
3.4. PEA3 binds to the EBS within CR2 in NCCIT cells
We performed ChIP assays to determine whether PEA3 can
directly interact with CR2 (containing the putative EBS) in native
chromatin of undifferentiated NCCIT cells. (Fig. 7). We prepared
chromatin from undifferentiated NCCIT cells expressing OCT4 and
PEA3, pulled down PEA3-bound chromatin with an anti-PEA3 anti-
body, and ampliﬁed the region containing the putative PEA3-bind-
ing site by real-time PCR with CR2-speciﬁc primers. Three pairs of
primers were used: one pair to amplify CR2 (1513 to 1316,
depicted as ‘b’), which spans the putative EBS, and two pairs to
Fig. 3. OCT4 promoter activity is activated by PEA3 in a dose-dependent manner, and activation requires the PEA3 transactivation domain. (A) Schematic diagram of OCT4
promoter reporter (-2601-Luc) and TAD-truncated PEA3 dominant-negative (DN) constructs. Four conserved regions (CRs) of the OCT4 promoter and functional domains of
PEA3 and PEA3 DN are indicated by black boxes. (B) The OCT4 promoter reporter (-2601-Luc) was co-transfected into NCCIT cells along with increasing amounts of PEA3
expression vector. (C) The OCT4 promoter reporter (-2601-Luc) was co-transfected into NCCIT cells along with increasing amounts of PEA3 DN expression vector and a
constant amount of exogenous PEA3. Values labeled with different letters are signiﬁcantly different from one another (P < 0.05).
Fig. 4. The effect of PEA3 on the transcriptional activity of a series of OCT4 promoter deletion mutants. (A) Schematic diagram of OCT4 promoter serial deletion mutants. (B)
Each serial deletion mutant of the OCT4 promoter construct was co-transfected into NCCIT cells along with PEA3 expression vector. ⁄P < 0.05.
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136, depicted as ‘c’) used as negative controls for PEA3 recruit-
ment (Fig. 7A). Region b (1513 to 1316), which contains the
putative EBS, was signiﬁcantly enriched compared to regions a
and c (Fig. 7B). These results demonstrate that PEA3 can directly
bind to the putative EBS within CR2; this binding is likely to be
involved in PEA3-mediated activation of OCT4 promoter activity.
ETS family proteins recognize the core consensus sequence
50-GGA(A/T)-30 via the ETS DNA-binding domain [5–7]. The ETS
domain is usually located within the C-terminal region of theprotein as a winged helix-turn-helix structural motif; this domain
mediates binding to purine-rich sites, usually containing the afore-
mentioned consensus sequence, which is present in the promoter
and enhancer regions of target genes [48–51]. PEA3 acts as an acti-
vator by binding to the DNA sequences surrounding the 50-GGA
(A/T)-30 core. For example, in breast cancer cells, PEA3 induces vas-
cular endothelial growth factor promoter activity by binding to a
motif in the promoter region (298TTTCCT293) [18]. Likewise, also
in breast cancer cells, PEA3 upregulates CXC chemokine receptor
type 4 promoter activity via binding to a motif in the upstream
Fig. 5. OCT4 promoter conserved region 2 (CR2) is important for the transcriptional activity. (A) Schematic representation of OCT4 promoter constructs (-2601-Luc and CR2-
ti-Luc) and derivatives containing mutations in the putative ETS binding site (EBS) (-2601⁄-Luc and CR2⁄-ti-Luc). The purple box indicates the putative EBS, and site-directed
mutagenesis of the binding site is indicated by an X. (B) Each reporter vector was co-transfected with PEA3 expression vector. ⁄⁄P < 0.01.
Fig. 6. Transcriptional activation of OCT4 promoter CR2 mediated by PEA3. (A) Schematic diagram of the exogenous minimal ti reporter vector (CR2-ti-Luc), PEA3, and PEA3
DN. (B) CR2-ti-Luc was co-transfected into in NCCIT cells along with increasing amounts of PEA3 expression vector. (C) CR2-ti-Luc was co-transfected into NCCIT cells along
with increasing amounts of PEA3 DN and a constant amount of PEA3 expression vector. Values labeled with different letters are signiﬁcantly different from one another
(P < 0.05).
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tors interact with TATA-less promoters, and especially suppression
of Etsrp71, Elf3, and Spic reduced the transcription of the Oct3/4
gene, whose embryonic expression is regulated by such promoters,
suggesting that ETS factors play important roles in the regulation
of transcription with TATA-less promoters in preimplantation
development [50,52,53]. PEA3 and other ETS factors may be also
required to initiate transcription from TATA-less promoters via
interactions with other transcription factors [50,54–56]. For
instance, PEA3 activates transcription of the Gamma-glutamyl
transpeptidase promoter IV, one of the TATA-less promoters, and
an adjacent Sp1 binding motif is required to maintain promoteractivity [54]. We have also characterized cis-regulatory elements
in the OCT4 promoter and found that Sp family and orphan nuclear
receptors play important roles in OCT4 transcription [34,37,44].
Nevertheless, their transcriptional and functional co-relationship
remains to be investigated in further study. To step forward, we
identiﬁed EBS within the OCT4 promoter and demonstrated that
PEA3 acts as a transcriptional activator of OCT4 expression by
directly binding to the EBS in CR2 of the proximal enhancer. Fur-
thermore, this activation plays a physiologically important role in
regulating cell proliferation in NCCIT cells. These ﬁndings contrib-
ute to our understanding on the role of stem cell-related oncogenic
factors in tumorigenesis and pluripotency.
Fig. 7. PEA3 binds to the ETS binding site within the OCT4 promoter CR2 in NCCIT cells. (A) Schematic diagram of the locations of OCT4 primer pairs corresponding to
positions 2613 to 2396 (a), 1513 to 1316 (b), and 237 to 136 (c). (B) Enrichment of the putative PEA3 binding site was analyzed by real-time PCR. The enrichment of
the OCT4 promoter CR2 target region (1513 to 1316) was visualized by gel electrophoresis. Values labeled with different letters (, §) are signiﬁcantly different from one
another (P < 0.05).
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